NAMS: NewAmsterdam Pharma Company Projected Revenue

NAMS (NewAmsterdam Pharma N.V.) - company brandmark

NewAmsterdam Pharma (NAMS) relies on the patent protection of its unique class of drugs, which will ensure premium pricing. The innovative drug Obicetrapib replaces costly injections for the treatment of high cholesterol by inhibiting CETP. However, the business's success is tied to a single cardio-metabolic product and the results of clinical trials. The company's sales volume projection on GURU.Markets contains data where the value has settled at 0.03.

Company Projected Revenue: NewAmsterdam Pharma Corp (NAMS) for 06/21/2023 - 11/17/2026

Analytical breakdowns and data insights for company NewAmsterdam Pharma Corp (NAMS)

Fundamental company analysis:NAMS NewAmsterdam Pharma N.V.
Signature product of NewAmsterdam Pharma N.V.

The indicator transforms retrospective reporting into a dynamic revenue forecast by aggregating analyst consensus estimates to rapidly determine the asset's fundamental value. By analyzing the firm's sales volume expectations, investors can see the commercialization potential of Obicetrapib, where replacing costly injections with an affordable cholesterol-fighting pill directly determines the future cash flow trajectory of NewAmsterdam Pharma (NAMS).

Who NewAmsterdam Pharma competes with

Projected Sales Volume ASND|Company Projected Revenue MDGL (Madrigal Pharmaceuticals Inc)|Company Projected Revenue corcept.com CORT|Rhythm Corp (RYTM) - Company Expected Sales Volume|AKRO - Company Projected Revenue|MTSR: Company Projected Revenue|MLTX: Projected Sales Volume|CRNX - Company Future Sales|Company Projected Revenue Soleno Therapeutics Corp|Amicus Corp (FOLD) - Company Future Sales|Company Projected Revenue 89bio.com (ETNB)|Company Future Sales Volume Agios Pharmaceuticals AGIO|Company Projected Revenue Structure Therapeutics Inc GPCR|MDXG - Company Future Sales Volume|rezolutebio.com - Projected Sales Volume|Company Expected Sales Volume Lexicon Pharmaceuticals|MBX (MBX Biosciences Inc) - Company Future Sales Volume|ALT - Company Future Sales|AARD (Aardvark Therapeutics Corp) - Projected Sales Volume|Sagimet Biosciences, Inc. (SGMT) - Company Future Sales|Projected Sales Volume BIOA|BMEA - Company Expected Sales Volume|Projected Sales Volume QNCX (Quince Therapeutics, Inc.)|fractyl.com (GUTS) - Company Expected Sales Volume|vTv Therapeutics Inc - Projected Sales Volume|ATPC - Projected Sales Volume|Pluri Inc. (PLUR) - Company Projected Revenue|Company Future Sales Volume Synlogic, Inc.|Company Future Sales Volume LPCN|Company Projected Revenue MTNB|Company Projected Revenue sprucebiosciences.com (SPRB)|Galecto - Company Revenue Forecast|Company Projected Revenue Carmell Corp CTCX|LUMO - Company Future Sales Volume|ONVO - Company Projected Revenue|radiuspharm.com (RDUS) - Company Future Sales Volume